Analytical Data
-
基因名
Lpa
- Application
-
别名
Lpa；Liprin-alpha-2
-
种属
Human
-
表达系统
E. coli
-
标签
His tag N-Terminus
-
纯度
Greater than 90% as determined by SDS-PAGE.
-
蛋白编号
Q92633
-
表达区间
1-364aa
-
氨基酸序列
MAAISTSIPVISQPQFTAMNEPQCFYNESIAFFYNRSGKHLATEWNTVSK LVMGLGITVCIFIMLANLLVMVAIYVNRRFHFPIYYLMANLAAADFFAGL AYFYLMFNTGPNTRRLTVSTWLLRQGLIDTSLTASVANLLAIAIERHITV FRMQLHTRMSNRRVVVVIVVIWTMAIVMGAIPSVGWNCICDIENCSNMAP LYSDSYLVFWAIFNLVTFVVMVVLYAHIFGYVRQRTMRMSRHSSGPRRNR DTMMSLLKTVVIVLGAFIICWTPGLVLLLLDVCCPQCDVLAYEKFFLLLA EFNSAMNPIIYSYRDKEMSATFRQILCCQRSENPTGPTEGSDRSASSLNH TILAGVHSNDHSVV
-
分子量
68 kDa
-
内毒素
< 1.0 EU per μg protein as determined by the LAL method.
-
性状
Freeze-dried powder
-
缓冲液
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
复溶方法
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- 个性化定制
-
稳定性测试
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
保存条件 & 期限
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
运输条件
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
Lpa (Lipoprotein(a)) is a lipoprotein variant that consists of low-density lipoprotein (LDL) and a specific protein known as apolipoprotein(a). Elevated levels of Lpa in the bloodstream have been identified as a significant risk factor for cardiovascular diseases, including atherosclerosis, heart attacks, and strokes. The unique structure of Lpa, particularly the varying size of apolipoprotein(a) due to genetic polymorphisms, complicates its study and has led to challenges in understanding its biological functions and implications. As traditional lipid-lowering therapies do not effectively reduce Lpa levels, there is a critical need for targeted research to explore Lpa's role in lipid metabolism and its contribution to cardiovascular pathology. Recent advancements in recombinant protein technology have paved the way for the production of Lpa in laboratory settings, enabling researchers to study its properties, mechanisms of action, and interactions with other lipids and proteins in greater detail. The development of novel therapeutic strategies that specifically target Lpa represents a promising avenue for reducing cardiovascular risk and improving patient outcomes. Overall, ongoing research in Lpa recombinant proteins aims to unravel the complexities of this lipoprotein and its potential as a therapeutic target in cardiovascular disease management.
